Refers to a pyrazole derivative Compound of formula (i) where: q is selected from (a) and (b) W is N (R8) - C (o) -, - C (o) n (R8), alquileno C1 - 6, among others V is alquileno C1 6 r1 is h, alkyl, optionally substituted C1 - 7 - 6, alquenilo C2, C1 C2 alkoxyl alquinilo - 6, - 7, among others R2 is alq Uilo alquenilo C2 - C3 - 7, 6 Hydroxy alkyl, hydroxyl, c1-4, among others R3 is H, alkyl C1 - 6Alkoxyl C1 - C3 - 7 6, cycloalkyl, among others R8 is H, alkyl C1 - 7 Hydroxy alkyl, cycloalkyl C1 - C3 - 4, 7 among others, and are independently r5a R5 C1 - 6 h, alkyl, Halo c1-4 alkyl, or together form an oxo group or a cycloalkyl Group C3 - 7.R6 is C1 - C6 alkyl aryl - 6, 7 - 10, cicloaquilo C3, among others R7 is C1 - 7 h, alkyl, Halo c1-4 alkyl n is an integer from 1 to 3, p is an integer from 0 to 6.Preferred compounds are: N - (3,4 - difluoro - benzyl) - 3 - (1 - (4 - 5 - fluoro - benzyl) - oxo - 1h-1,2,4-triazole - 2 (5H) - yl) - 1H pyrazole carboxamide - 5 3 - (3 - (4 - fluoro - benzyl Co.) - 2 - oxo - triazin-1-yl) - N - ((3 - 5 - methyl isoxazole - yl) methyl) - 1H pyrazole - 5 - carboxamide among others. It also relates to a Pharmaceutical composition.This Compound is an inhibitor of the Enzyme Stearoyl COA desaturase (SCD), being useful in the treatment of diabetes, obesity, cardiovascular disease, Dermatological DisordersSE REFIERE A UN COMPUESTO DERIVADO DE PIRAZOL DE FORMULA (I) DONDE: Q SE SELECCIONA ENTRE (A) Y( B) W ES -N(R8)C(O)-, -C(O)N(R8)-, ALQUILENO C1-6, ENTRE OTROS V ES ALQUILENO C1-6 R1 ES H, ALQUILO C1-7 OPCIONALMENTE SUSTITUIDO, ALQUENILO C2-6, ALQUINILO C2-6, ALCOXILO C1-7, ENTRE OTROS R2 ES ALQUILO C3-7, ALQUENILO C2-6, HIDROXILO, HIDROXI-ALQUILO C1-4, ENTRE OTROS R3 ES H, ALQUILO C1-6, ALCOXILO C1-6, CICLOALQUILO C3-7, ENTRE OTROS R8 ES H, ALQUILO C1-7, HIDROXI-ALQUILO C1-4, CICLOALQUILO C3-7 ENTRE OTROS R5 Y R5a SON INDEPENDIENTEMENTE H, ALQUILO C1-6, HALO-ALQUILO C1-4, ENTRE OTROS O JUNTOS FORMAN UN GRUPO OXO O UN GRUPO CICLOALQUILO C3-7.
